Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 48 No. 4
PSYCHOPHARMACOLOGY BULLETIN

VOL 48 No. 4

Articles in This Issue

LETTERS TO THE EDITOR

A Perspective on Adolescent Chronic Pain Dismissal

Jacquelin Peck, Omar Viswanath
Optimal management of chronic pain is complex and often daunting. In the pediatric and adolescent population, care-givers face additional biases in the face of youth and perceived states of health, which compounds this challenge and...
Pages 10-12 Read Article
COMPLICATED CASE HISTORIES

Induction of Psychosis by Cyclobenzaprine

Johan Y. Cohen, Amélie Guilbault
Due to the stringent regulatory environment for therapeutics, common side-effects of drugs in the general population are largely well-documented. This is however less the case with certain patient subgroups who may exhibit significant adverse responses...
Pages 15-19 Read Article
COMPLICATED CASE HISTORIES

A Case of Hyper Sexuality Probably Associated with Clozapine

Sereen Rose Thomson, Navin Patil, Balaji Ommurugan, Rajesh Krishna Bhandary
Introduction Schizophrenia treatment needs to cover several psychological interventions and pharmacological treatment for stabilizing the disease course and decreasing relapses. Sexual side effects are a major hindrance to patients and lead to decreased adherence to...
Pages 20-24 Read Article
ORIGINAL RESEARCH

Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis

Sofia Medrano, Amal Abdel-Baki, Emmanuel Stip, Stéphane Potvin
Abstract Poor adherence to antipsychotics, which affects outcome, is frequent in first episode psychosis (FEP). Most randomized studies demonstrate no superiority of long-acting injectable antipsychotics (LAI-AP) over oral antipsychotics (OAP). However, participants in these studies...
Pages 25-61 Read Article
ORIGINAL RESEARCH

Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Willie R. Earley, Hua Guo, György Németh, Judit Harsányi, Michael E. Thase
Cariprazine is an atypical antipsychotic currently under investigation as an adjunctive to antidepressant treatment (ADT) for patients with major depressive disorder (MDD). Here results of an 18- to 19-week randomized double-blind placebo-controlled Phase 3 study...
Pages 62-80 Read Article